Published in Eur J Dermatol on April 03, 2006
Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manag (2008) 1.04
Development and psychometric validation of the REFlective evaLuation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire: a common measure of plaque-type psoriasis severity and treatment efficacy for patients and clinicians. J Eur Acad Dermatol Venereol (2014) 0.75
Responsiveness to change and interpretability of the simplified psoriasis index. J Invest Dermatol (2013) 0.75
Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. Clin Cosmet Investig Dermatol (2017) 0.75
Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res (2006) 8.26
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (2006) 4.26
Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci (2002) 4.23
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med (2014) 3.36
A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med (2003) 3.20
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum (2009) 2.49
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A (2005) 2.47
Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell (2006) 2.43
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol (2007) 2.26
The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology (2005) 1.99
ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci (2005) 1.99
Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochem J (2010) 1.93
Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc Res (2005) 1.77
Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol (2002) 1.71
Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci (2002) 1.69
Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. J Cell Sci (2003) 1.68
Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem (2005) 1.59
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol (2006) 1.59
Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. J Invest Dermatol (2006) 1.59
ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem Biophys Res Commun (2002) 1.55
Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark. Acta Derm Venereol (2010) 1.51
The Janus faces of allopurinol-allopurinol hypersensitivity syndrome. Am J Med (2008) 1.47
Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1. Proc Natl Acad Sci U S A (2012) 1.46
Effectiveness of inpatient treatment on quality of life and clinical disease severity in atopic dermatitis and psoriasis vulgaris - a prospective study. Dermatology (2007) 1.43
Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol (2006) 1.42
Matrix metalloproteinases in disease and repair processes in the anterior segment. Surv Ophthalmol (2002) 1.41
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum (2012) 1.40
Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab. Acta Derm Venereol (2008) 1.39
Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem (2006) 1.34
Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2012) 1.33
Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR). J Biol Chem (2003) 1.32
Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J Invest Dermatol (2003) 1.30
Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol (2002) 1.29
Human diabetic corneas preserve wound healing, basement membrane, integrin and MMP-10 differences from normal corneas in organ culture. Exp Eye Res (2003) 1.26
Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci U S A (2011) 1.26
Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J Biol Chem (2004) 1.24
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res (2002) 1.23
Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 1.22
Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration. J Biol Chem (2007) 1.22
Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem (2002) 1.22
The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol (2008) 1.21
Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol (2009) 1.20
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med (2015) 1.20
Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem (2004) 1.18
Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol (2002) 1.18
Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes. Arthritis Res Ther (2011) 1.15
1alpha,25(OH)(2)D(3) regulates NF-kappaB DNA binding activity in cultured normal human keratinocytes through an increase in IkappaBalpha expression. Arch Dermatol Res (2004) 1.14
Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am J Pathol (2005) 1.14
The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett (2002) 1.13
Increased matrix metalloproteinase-13 production with aging by human articular chondrocytes in response to catabolic stimuli. J Gerontol A Biol Sci Med Sci (2005) 1.13
Temporal and spatial expression of matrix metalloproteinases during wound healing of human corneal tissue. Exp Eye Res (2003) 1.13
A heterogeneous in vitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis. PLoS One (2012) 1.12
A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis (2009) 1.11
Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J Invest Dermatol (2003) 1.09
Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1. J Biol Chem (2007) 1.09
Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol (2006) 1.08
A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol (2010) 1.08
Distinct roles of dopamine and subthalamic nucleus in learning and probabilistic decision making. Brain (2012) 1.07
The activity of caspase-1 is increased in lesional psoriatic epidermis. J Invest Dermatol (2007) 1.07
The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function. Biochemistry (2010) 1.06
Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology (2002) 1.06
Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology (2011) 1.05
Management of chronic hand eczema. Contact Dermatitis (2007) 1.05
Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases. Cancer Res (2006) 1.04
Phosphorylation-dependent interactions between ADAM15 cytoplasmic domain and Src family protein-tyrosine kinases. J Biol Chem (2001) 1.04
IL-20 gene expression is induced by IL-1beta through mitogen-activated protein kinase and NF-kappaB-dependent mechanisms. J Invest Dermatol (2007) 1.04
Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Dermatol (2003) 1.03
Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition. J Biol Chem (2004) 1.03
The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology (2007) 1.02
The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3. FEBS Lett (2002) 1.02
Unveiling the surface epitopes that render tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase. J Biol Chem (2003) 1.02
Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-{alpha}-converting enzyme. J Biol Chem (2005) 1.01
Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb Haemost (2002) 1.01
TIMP-3 inhibition of ADAMTS-4 (Aggrecanase-1) is modulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4. J Biol Chem (2007) 1.01
Family-based investigation of the C677T polymorphism of the methylenetetrahydrofolate reductase gene in ischaemic heart disease. Atherosclerosis (2002) 1.01
Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical. Cancer Res (2005) 1.00
Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics (2003) 1.00
Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA. J Thorac Oncol (2010) 1.00
The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol (2011) 0.99
Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13. FEBS Lett (2002) 0.99
Human corneal epithelial cells require MMP-1 for HGF-mediated migration on collagen I. Invest Ophthalmol Vis Sci (2003) 0.98
Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional study. Eur J Dermatol (2012) 0.98
MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J Cell Sci (2010) 0.97
Lactoferricin mediates anabolic and anti-catabolic effects in the intervertebral disc. J Cell Physiol (2012) 0.97
Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect. J Invest Dermatol (2007) 0.96
An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther (2005) 0.96
Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-alpha-converting enzyme. Biochem J (2002) 0.96
Malignant Langerhans cell tumor: a case with a favorable outcome associated with the absence of blood dendritic cell proliferation. J Am Acad Dermatol (2003) 0.95
MK2 regulates the early stages of skin tumor promotion. Carcinogenesis (2009) 0.95
Caspase-5 expression is upregulated in lesional psoriatic skin. J Invest Dermatol (2010) 0.95
Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS One (2012) 0.95
Tumor necrosis factor α-mediated induction of interleukin 17C in human keratinocytes is controlled by nuclear factor κB. J Biol Chem (2011) 0.94
A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol (2008) 0.94
Differential expression of matrix metalloproteinases during impaired wound healing of the diabetes mouse. J Invest Dermatol (2002) 0.94
Role of the netrin-like domain of procollagen C-proteinase enhancer-1 in the control of metalloproteinase activity. J Biol Chem (2010) 0.93
Use of a multiple-enzyme/multiple-reagent assay system to quantify activity levels in samples containing mixtures of matrix metalloproteinases. Biochemistry (2004) 0.92